Carbonyl erastin derivatives as genotype-specific anticancer agentsTechnology #cu14068
Questions about this technology? Ask a Technology Manager
Erastin is a recently identified small molecule with specific antitumor activity that does not harm healthy cells. Erastin targets certain cancers with a specific form of the oncogene RAS, and kills tumor cells through a pathway called ferroptosis. However, conventional erastins lack the stability, selectivity, and potency that make them viable therapeutics for cancer. To address these challenges, this technology is an ensemble of erastin analogs with improved selectivity, potency, and stability compared to conventional erastin. The ensemble initiates cancer cell death through the same ferroptosis pathway, but tolerates a wider variety of RAS mutants and is therefore a more robust treatment. This technology has potential to be used as a collection of genotype-selective anticancer agents.
Erastin analogs with greater stability and potency than conventional erastin with specificity for cancer genotypes
The ensemble of erastin derivatives established in this technology display significantly enhanced stability and potency, resulting in a superior set of anticancer drug candidates. The derivatives also display a keener specificity for certain RAS-type cancers, which improve the protection of healthy cells. Moreover, the use of straightforward chemistry to achieve a significant increase in anti-cancer activity represents an attractive platform to develop inexpensive and effective anti-tumor drugs. The genotype specificity of these erastin derivatives can be used in conjunction with personalized medicine to tailor chemotherapy of RAS-type tumors.
The minor structural modification of erastin results in increased specificity, potency, and stability in in vitro cellular assays when compared to conventional erastin.
- Pharmaceutical treatment for certain RAS-type tumors
- Genotype-selective anticancer treatment
- Potent induction of cell death with minimal damage to healthy cells
- Tool for researchers investigating the effect of RAS mutations in ferroptosis induction
- Compound for studying the function of RAS mutants in cancer research
- Cancer specific
- Does not harm healthy cells
- Individual compounds in the ensemble demonstrate genotype specificity to different RAS tumors
- Increased stability and potency than erastin
Patent Pending (US 20160332974)
Tech Ventures Reference: IR CU14068
Dolma S, Lessnick SL, Hahn WC, Stockwell BR. “Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells” Cancer Cell. 2003 Mar;3(3):285-96.
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, Morrison B 3rd, Stockwell BR. “Ferroptosis: an iron-dependent form of nonapoptotic cell death” Cell. 2012 May 25;149(5):1060-72.
Dixon SJ, Patel DN, Welsch M, Skouta R, Lee ED, Hayano M, Thomas AG, Gleason CE, Tatonetti NP, Slusher BS, Stockwell BR. “Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis” Elife. 2014 May 20;3:e02523.